CBIH Cannabis Bioscience International Holdings, Inc.
Services-Commercial Physical & Biological Research · OTC · SEC CIK 1411057 · Fiscal year ends 05/31
Financial factors as of 2026-02-28 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-64.1%
TTM net income YoY-8.9%
TTM EPS YoY-461.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin78.8%
Operating margin-322.6%
Net margin-416.8%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-6,272.5%
ROIC (approx.)—
Asset turnover15.05x
Leverage & solvency
Liabilities / assets95,121.4%
Debt / equity—
Current ratio0.00x
Interest coverage-2.68x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-3,008.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-05-31 | FY20242024-05-31 | FY20232023-05-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $303,022 | $248,841 | $316,825 |
| Cost of revenue | $40,106 | $45,599 | $93,450 |
| Gross profit | $262,916 | $203,242 | $223,375 |
| SG&A expense | $101,906 | $123,759 | $177,110 |
| Operating income | -$421,365 | -$486,140 | -$983,371 |
| Interest expense | $136,262 | $154,206 | $90,973 |
| Income tax | — | $0 | $0 |
| Net income | -$548,820 | -$651,345 | -$1.03M |
| EPS (basic) | -0.00 | -0.00 | -0.00 |
| EPS (diluted) | -0.00 | -0.00 | -0.00 |
| Weighted avg. shares (diluted) | 10.72B | 10.32B | 9.00B |
| Balance sheet | |||
| Cash & equivalents | $12,952 | $755 | $8,913 |
| Receivables | $6,380 | $20,139 | $9,951 |
| Current assets | $29,085 | $21,492 | $19,462 |
| Total assets | $31,880 | $57,162 | $43,382 |
| Current liabilities | $945,963 | $881,909 | $385,547 |
| Short-term debt | $14,592 | $7,054 | $14,592 |
| Long-term debt | $249,500 | $249,361 | $249,500 |
| Total debt | $264,092 | $256,415 | $264,092 |
| Total liabilities | $1.20M | $1.14M | $635,047 |
| Shareholders' equity | -$1.16M | -$1.08M | -$591,665 |
| Net debt | $251,140 | $255,660 | $255,179 |
| Shares outstanding | 11.63B | 10.43B | 10.06B |
| Cash flow statement | |||
| Operating cash flow | -$329,627 | -$479,382 | -$898,367 |
| Financing cash flow | $341,824 | $471,224 | $875,298 |
| Stock-based compensation | — | $0 | $12,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.